{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:38:43Z","timestamp":1777631923536,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cpcardiol.2025.103171","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:03:31Z","timestamp":1757491411000},"page":"103171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Knowledge mapping of SGLT2-inhibitors and cardiovascular outcomes: A bibliometric analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Aysa","family":"Rezabakhsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadis","family":"Iraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashot","family":"Avagimyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Aghajanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinaida","family":"Jndoyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Mirzoyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Meddahi-Pell\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Pavon-Djavid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Barzegri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2025.103171_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109068","article-title":"Age different effects of SGLT2 inhibitors on body composition in individuals with type 2 diabetes: a retrospective cohort study","volume":"39","author":"Miyoshi","year":"2025","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0002","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1039\/C8MD00183A","article-title":"Sodium\u2013glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class","volume":"9","author":"da Silva","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0003","doi-asserted-by":"crossref","first-page":"126","DOI":"10.35401\/2541-9897-2024-9-4-126-135","article-title":"Protective potential of sodium-glucose cotransporter 2 inhibitors in internal medicine (Part 1)","volume":"9","author":"Avagimyan","year":"2024","journal-title":"Innov Med Kuban"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0004","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112050","article-title":"A critical review on SGLT2 inhibitors for diabetes mellitus, renal health, and cardiovascular conditions","volume":"221","author":"Kumar","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0008","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2018-02254","article-title":"Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin","volume":"104","author":"Yoshida","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0009","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0010","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0011","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium\u2013glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1437760","article-title":"Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/10408363.2024.2361012","article-title":"SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives","volume":"61","author":"Tan","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 Inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ejhf.3464","article-title":"Timing of sodium\u2013glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: a population-based cohort study","volume":"27","author":"Wu","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103171_bib0017","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ejhf.3560","article-title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)","volume":"27","author":"Carberry","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0018","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/ejhf.2968","article-title":"Similarities and distinctions between acetazolamide and sodium\u2013glucose cotransporter 2 inhibitors in patients with acute heart failure: key insights into ADVOR and EMPULSE","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.35401\/2541-9897-2025-10-1-101-109","article-title":"Protective potential of sodium-glucose cotransporter 2 inhibitors in internal medicine (Part 2)","volume":"10","author":"Avagimyan","year":"2025","journal-title":"Innov Med Kuban"},{"issue":"22","key":"10.1016\/j.cpcardiol.2025.103171_bib0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0021","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0022","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England J Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0023","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New England J Med"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103171_bib0024","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0026","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103171_bib0027","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0028","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103171_bib0029","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"New England J Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:09:02Z","timestamp":1761818942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0146280625001914"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103171","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Knowledge mapping of SGLT2-inhibitors and cardiovascular outcomes: A bibliometric analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103171"}}